Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRO-BOOST-N: A Randomized Phase II/III Trial Evaluating Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer Using an Ultrahypofractionated Whole-Pelvis Radiotherapy Platform

NCT07426094 is registered in ClinicalTrials.gov with Affidea Nu-med Center of Oncological DIagnostics and Therapy as lead sponsor.

NCT NCT07426094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07426094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRO-BOOST-N: A Randomized Phase II/III Trial Evaluating Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer Using an Ultrahypofractionated Whole-Pelvis Radiotherapy Platform
Lead sponsor
Affidea Nu-med Center of Oncological DIagnostics and Therapy
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 19, 2026
Completion date
December 1, 2035
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brachytherapy, dose escalation: solid tumors, prostate cancer, regionally advanced prostate cancer, stereotactic body radiation therapy (sbrt)